IRONWOOD PHARMACEUTICALS, INC. Earnings Per Share (Basic)
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Earnings Per Share (Basic) of $0.31 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-06
- IRONWOOD PHARMACEUTICALS, INC. earnings per share, basic for the quarter ending 2026-06-30 was $0.31, a 106.67% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. earnings per share, basic for the quarter ending 2026-03-31 was $0.25.
- IRONWOOD PHARMACEUTICALS, INC. earnings per share, basic for the quarter ending 2025-12-31 was -$0.01, a 200.00% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. earnings per share, basic for the quarter ending 2025-09-30 was $0.25, a 1150.00% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. earnings per share, basic for fiscal 2025 was $0.15, a 1400.00% increase from fiscal 2024.
- IRONWOOD PHARMACEUTICALS, INC. earnings per share, basic for fiscal 2024 was $0.01.
- IRONWOOD PHARMACEUTICALS, INC. earnings per share, basic for fiscal 2023 was -$6.45, a 670.80% decline from fiscal 2022.
- IRONWOOD PHARMACEUTICALS, INC. earnings per share, basic for fiscal 2022 was $1.13, a 65.34% decline from fiscal 2021.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.31 10-Q · filed 2026-08-06 | $0.56 10-Q · filed 2026-08-06 | $0.55 derived: net income ÷ weighted average shares · filed 2026-08-06 | $0.80 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2026-03-31 | $0.25 10-Q · filed 2026-05-07 | $0.24 derived: net income ÷ weighted average shares · filed 2026-05-07 | $0.48 derived: net income ÷ weighted average shares · filed 2026-05-07 | $0.63 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-12-31 | -$0.01 10-K · filed 2026-02-26 | $0.23 derived: net income ÷ weighted average shares · filed 2026-02-26 | $0.38 derived: net income ÷ weighted average shares · filed 2026-08-06 | $0.15 10-K · filed 2026-02-26 |
| 2025-09-30 | $0.25 10-K · filed 2026-02-26 | $0.39 derived: net income ÷ weighted average shares · filed 2026-08-06 | $0.16 10-Q · filed 2025-11-10 | $0.18 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-06-30 | $0.15 10-Q · filed 2026-08-06 | -$0.09 10-Q · filed 2026-08-06 | -$0.07 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$0.05 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-03-31 | -$0.23 10-Q · filed 2026-05-07 | -$0.22 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$0.20 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$0.20 derived: net income ÷ weighted average shares · filed 2026-05-07 |
| 2024-12-31 | $0.01 10-K · filed 2026-02-26 | $0.04 derived: net income ÷ weighted average shares · filed 2026-02-26 | $0.03 derived: net income ÷ weighted average shares · filed 2026-02-26 | $0.01 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.02 10-K · filed 2026-02-26 | $0.02 derived: net income ÷ weighted average shares · filed 2025-11-10 | -$0.01 10-Q · filed 2025-11-10 | -$0.02 derived: net income ÷ weighted average shares · filed 2025-11-10 |
| 2024-06-30 | -$0.01 10-K · filed 2026-02-26 | -$0.03 10-Q · filed 2025-08-11 | -$0.04 derived: net income ÷ weighted average shares · filed 2025-08-11 | $0.06 derived: net income ÷ weighted average shares · filed 2025-08-11 |
| 2024-03-31 | -$0.03 10-K · filed 2026-02-26 | -$0.03 derived: net income ÷ weighted average shares · filed 2025-05-12 | $0.06 derived: net income ÷ weighted average shares · filed 2025-05-12 | |
| 2023-12-31 | -$0.01 10-K · filed 2025-03-31 | $0.09 derived: net income ÷ weighted average shares · filed 2025-03-31 | -$6.45 10-K · filed 2025-03-31 | |
| 2023-09-30 | $0.10 10-K · filed 2025-03-31 | -$6.45 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | -$6.84 10-K · filed 2025-03-31 | -$6.56 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $0.30 10-K · filed 2025-03-31 | $0.61 derived: net income ÷ weighted average shares · filed 2025-03-31 | $0.94 derived: net income ÷ weighted average shares · filed 2025-03-31 | $1.19 derived: net income ÷ weighted average shares · filed 2025-03-31 |
| 2022-12-31 | $0.32 10-K · filed 2024-02-16 | $0.65 derived: net income ÷ weighted average shares · filed 2025-03-31 | $0.89 derived: net income ÷ weighted average shares · filed 2025-03-31 | $1.13 10-K · filed 2025-03-31 |
| 2022-09-30 | $0.33 10-K · filed 2024-02-16 | $0.57 derived: net income ÷ weighted average shares · filed 2023-11-09 | $0.82 10-Q · filed 2023-11-09 | $1.07 derived: net income ÷ weighted average shares · filed 2024-02-16 |
| 2022-06-30 | $0.24 10-K · filed 2024-02-16 | $0.49 10-Q · filed 2023-08-09 | $0.74 derived: net income ÷ weighted average shares · filed 2024-02-16 | $1.09 derived: net income ÷ weighted average shares · filed 2024-02-16 |
| 2022-03-31 | $0.25 10-K · filed 2024-02-16 | $0.50 derived: net income ÷ weighted average shares · filed 2024-02-16 | $0.84 derived: net income ÷ weighted average shares · filed 2024-02-16 | $3.27 derived: net income ÷ weighted average shares · filed 2024-02-16 |
| 2021-12-31 | $0.25 10-K · filed 2023-02-16 | $0.60 derived: net income ÷ weighted average shares · filed 2024-02-16 | $3.00 derived: net income ÷ weighted average shares · filed 2024-02-16 | $3.26 10-K · filed 2024-02-16 |
| 2021-09-30 | $0.34 10-K · filed 2023-02-16 | $2.75 derived: net income ÷ weighted average shares · filed 2022-11-03 | $3.01 10-Q · filed 2022-11-03 | $3.28 derived: net income ÷ weighted average shares · filed 2023-02-16 |
| 2021-06-30 | $2.42 10-K · filed 2023-02-16 | $2.67 10-Q · filed 2022-08-04 | $2.95 derived: net income ÷ weighted average shares · filed 2023-02-16 | $3.17 derived: net income ÷ weighted average shares · filed 2023-02-16 |
| 2021-03-31 | $0.25 10-K · filed 2023-02-16 | $0.52 derived: net income ÷ weighted average shares · filed 2023-02-16 | $0.73 derived: net income ÷ weighted average shares · filed 2023-02-16 | $0.89 derived: net income ÷ weighted average shares · filed 2023-02-16 |
| 2020-12-31 | $0.27 10-K · filed 2022-02-18 | $0.49 derived: net income ÷ weighted average shares · filed 2023-02-16 | $0.64 derived: net income ÷ weighted average shares · filed 2023-02-16 | $0.67 10-K · filed 2023-02-16 |
| 2020-09-30 | $0.22 10-K · filed 2022-02-18 | $0.37 derived: net income ÷ weighted average shares · filed 2021-11-04 | $0.40 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $0.16 10-K · filed 2022-02-18 | $0.18 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $0.02 10-K · filed 2022-02-18 | |||
| 2019-12-31 | $0.31 10-K · filed 2021-02-17 | $0.14 10-K · filed 2022-02-18 | ||
| 2019-09-30 | $0.13 10-K · filed 2021-02-17 | -$0.17 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | $0.08 10-K · filed 2021-02-17 | |||
| 2019-03-31 | -$0.38 10-K · filed 2021-02-17 | |||
| 2018-12-31 | -$1.85 10-K · filed 2021-02-17 | |||
| 2013-12-31 | -$0.43 10-K · filed 2014-02-07 | -$2.35 10-K · filed 2014-02-07 | ||
| 2013-09-30 | -$0.51 10-K · filed 2014-02-07 | -$1.93 10-Q · filed 2013-10-28 | ||
| 2013-06-30 | -$0.57 10-K · filed 2014-02-07 | |||
| 2013-03-31 | -$0.87 10-K · filed 2014-02-07 | |||
| 2012-12-31 | -$0.41 10-K · filed 2014-02-07 | -$0.68 10-K · filed 2014-02-07 | ||
| 2012-09-30 | $0.44 10-K · filed 2014-02-07 | $0.06 derived: net income ÷ weighted average shares · filed 2014-02-07 | -$0.27 10-Q · filed 2013-10-28 | -$0.34 derived: net income ÷ weighted average shares · filed 2014-02-07 |
| 2012-06-30 | -$0.38 10-K · filed 2014-02-07 | -$0.72 derived: net income ÷ weighted average shares · filed 2013-08-08 | -$0.80 derived: net income ÷ weighted average shares · filed 2014-02-07 | -$1.01 derived: net income ÷ weighted average shares · filed 2014-02-07 |
| 2012-03-31 | -$0.34 10-K · filed 2014-02-07 | -$0.42 derived: net income ÷ weighted average shares · filed 2014-02-07 | -$0.62 derived: net income ÷ weighted average shares · filed 2014-02-07 | -$0.81 derived: net income ÷ weighted average shares · filed 2014-02-07 |
| 2011-12-31 | -$0.07 10-K · filed 2013-02-21 | -$0.28 derived: net income ÷ weighted average shares · filed 2014-02-07 | -$0.46 derived: net income ÷ weighted average shares · filed 2014-02-07 | -$0.65 10-K · filed 2013-02-21 |
| 2011-09-30 | -$0.21 10-K · filed 2013-02-21 | -$0.40 derived: net income ÷ weighted average shares · filed 2012-11-06 | -$0.58 10-Q · filed 2012-11-06 | -$0.70 derived: net income ÷ weighted average shares · filed 2012-11-06 |
| 2011-06-30 | -$0.19 10-K · filed 2013-02-21 | -$0.37 10-Q · filed 2011-08-12 | -$0.49 derived: net income ÷ weighted average shares · filed 2012-08-07 | -$0.58 derived: net income ÷ weighted average shares · filed 2012-08-07 |
| 2011-03-31 | -$0.19 10-K · filed 2013-02-21 | -$0.30 derived: net income ÷ weighted average shares · filed 2012-05-10 | -$0.39 derived: net income ÷ weighted average shares · filed 2012-05-10 | -$0.56 derived: net income ÷ weighted average shares · filed 2012-05-10 |
| 2010-12-31 | -$0.12 derived: net income ÷ weighted average shares · filed 2012-02-29 | -$0.20 derived: net income ÷ weighted average shares · filed 2012-02-29 | -$0.38 derived: net income ÷ weighted average shares · filed 2012-02-29 | -$0.59 derived: net income ÷ weighted average shares · filed 2013-02-21 |
| 2010-09-30 | -$0.08 derived: net income ÷ weighted average shares · filed 2012-02-29 | -$0.26 derived: net income ÷ weighted average shares · filed 2012-02-29 | -$0.48 derived: net income ÷ weighted average shares · filed 2011-11-09 | |
| 2010-06-30 | -$0.18 10-Q · filed 2011-08-12 | -$0.41 10-Q · filed 2011-08-12 | ||
| 2009-12-31 | -$10.00 derived: net income ÷ weighted average shares · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |